You are here

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D’Haens GR Abstract BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition…

Read More

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease.

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Feb 17;: Authors: Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT Abstract BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn’s disease, even though some patients do not benefit from therapy. AIM: To assess the correlation between perianal fistula healing and trough levels of infliximab. METHODS: In this…

Read More

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply.

Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort – authors’ reply. Aliment Pharmacol Ther. 2017 Mar;45(6):856-857 Authors: Radford-Smith GL, Hartnell F, Doecke JD PMID: 28211631 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28211631?dopt=Abstract

Read More

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb 10;: Authors: Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, van den Brink GR, DʼHaens GR Abstract BACKGROUND: Several factors influencing the pharmacokinetics of infliximab (IFX) in inflammatory bowel disease (IBD) have been identified. We studied the impact of patient, disease, and treatment characteristics on clearance and immunogenicity of IFX in a real-world patient-with-IBD cohort. METHODS: Serum concentrations of IFX and antibodies to…

Read More

Infliximab not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Infliximab not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology. 2017 Feb 10;: Authors: Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M Abstract BACKGROUND AND AIMS: Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to increase risk of malignancy and lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis…

Read More

Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.

Related Articles Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J Crohns Colitis. 2017 Jan 27;: Authors: Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, Whiteoak S, Ker S, Perry K, Underhill C, Efrem E, Ahmed I, Cummings F Abstract BACKGROUND AND AIMS: Biosimilar infliximab CT-P13 offers the potential for large drug acquisition cost savings. However, there are limited published data regarding its efficacy, safety, and immunogenicity in inflammatory bowel disease [IBD], particularly in switching IBD patients from originator to biosimilar infliximab….

Read More

O-004 Application of Population Pharmacokinetic Modeling to Develop Individualized Infliximab Dosing Strategies in Pediatric Crohn’s Disease.

O-004 Application of Population Pharmacokinetic Modeling to Develop Individualized Infliximab Dosing Strategies in Pediatric Crohn’s Disease. Inflamm Bowel Dis. 2017 Feb;23 Suppl 1:S2 Authors: Frymoyer A, Hoekman D, de Meij T, Hummel T, Benninga M, Kindermann A, Piester T, Park KT Abstract BACKGROUND: Adequate infliximab (IFX) exposure is critical when treating Crohn’s disease (CD), and trough concentrations <3 μg/mL are associated with loss of response. However, the pharmacokinetics of IFX are highly variable in children with CD, and this has made IFX dosing challenging in this population. Model-based drug dosing…

Read More

O-006 Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multi-Center North American Experience.

O-006 Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multi-Center North American Experience. Inflamm Bowel Dis. 2017 Feb;23 Suppl 1:S2-S3 Authors: El-Matary W, Samson C, Crim A, Ali S, Grossman A Abstract BACKGROUND: Infusions of infliximab (IFX), a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) used to treat inflammatory bowel disease (IBD), can lead to development of anti-IFX antibodies (ATI), increasing risk of subsequent infusion reactions (IRs). IRs have been reported in as many as 5% of infusions and up to 10% to 20% of patients….

Read More

O-005 Combination Therapy with Methotrexate Does Not Change Infliximab Pharmacokinetics in Children with Inflammatory Bowel Disease.

O-005 Combination Therapy with Methotrexate Does Not Change Infliximab Pharmacokinetics in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb;23 Suppl 1:S2 Authors: Shakhnovich V, Van Haandel L, Becker M, Funk R Abstract BACKGROUND: There remains a question of equipoise regarding the use of anti-TNF-α agent (e.g., infliximab) monotherapy versus combination therapy with immunomodulators (e.g., methotrexate), for the treatment of pediatric Inflammatory Bowel Disease (IBD). The aim of this prospective cross-sectional study was to assess the impact of methotrexate (MTX) on infliximab (IFX) pharmacokinetics (i.e., serum trough levels) and…

Read More
<< Go Back